Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
Authors:
- 4 July 2014
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 140 (12) , 2107-2117
Abstract
The predictive value of excision repair cross-complementation group 1 (ERCC1) gene for survival and response to platinum-based chemotherapy in gastric cancer (GC) remains controversial. We performed a meta-analysis to clarify the precise estimation of the prognostic and predictive effect of ERCC1. A systematic literature search was conducted using PubMed, ScienceDirect, Wiley and American Society of Clinical Oncology (ASCO) before March 2014. Studies analyzing survival data and/or chemotherapy response in GC by ERCC1 status were identified. The principal outcome measures were hazard ratios (HRs) for survival and relative risks (RRs) for chemotherapy response. Pooled HRs and RRs were calculated using fixed- or random-effects models according to the heterogeneity. Twenty-one studies involving 1,628 patients met our inclusion criteria. High ERCC1 expression was significantly associated with shorter overall survival (OS) and lower response to chemotherapy in advanced GC patients receiving palliative chemotherapy (HR 1.83; 95 % CI 1.45–2.31; P < 0.001; RR 0.49; 95 % CI 0.38–0.62; P < 0.001). There was no significant difference in survival between high and low ERCC1 expression in adjuvant setting (OS: HR 1.38; 95 % CI 0.77–2.45; P = 0.276; EFS 0.72; 95 % CI 0.38–1.33; P = 0.291). Some evidence of heterogeneity and possible publication bias were discovered in few meta-analyses. High ERCC1 expression might be an adverse prognostic and a drug-resistance predictive factor for advanced GC patients. However, further studies with consistent ERCC1 assessment methodology are needed.Keywords
This publication has 34 references indexed in Scilit:
- Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerBMC Cancer, 2013
- Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatinChinese Journal of Cancer Research, 2011
- Removal of Reactive Oxygen Species-Induced 3′-Blocked Ends by XPF-ERCC1Chemical Research in Toxicology, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapyBritish Journal of Cancer, 2010
- Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survivalBritish Journal of Cancer, 2009
- Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behavioursEmerging Themes in Epidemiology, 2008
- ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimenBritish Journal of Cancer, 2008
- Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancerBritish Journal of Cancer, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007